Details for Patent: 10,603,293

« Back to Dashboard

Which drugs does patent 10,603,293 protect, and when does it expire?

Patent 10,603,293 protects PLIAGLIS and is included in one NDA.

This patent has seven patent family members in seven countries.

Summary for Patent: 10,603,293

Title:	Solid-forming local anesthetic formulations for pain control
Abstract:	Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.
Inventor(s):	Jie Zhang
Assignee:	Crescita Therapeutics Inc
Application Number:	US16/008,417
Patent Claim Types: see list of patent claims	Formulation;

Drugs Protected by US Patent 10,603,293

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Crescita Therap	PLIAGLIS	lidocaine; tetracaine	CREAM;TOPICAL	021717-001	Jun 29, 2006		RX	Yes	Yes	10,603,293		Y

International Family Members for US Patent 10,603,293

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011205730
Brazil	112012017554
Canada	2822220
China	102834096
European Patent Office	2523660
Mexico	2012008168